Managing Pediatric Growth Disorders

Managing Pediatric Growth Disorders

Evaluates short stature, tall stature, and abnormal growth velocity using WHO/CDC growth chart analysis, bone age radiography interpretation, mid-parental height targeting, endocrine workup algorithms, and criteria for growth hormone therapy referral. Differentiates normal variants (familial short stature, constitutional delay) from pathologic causes requiring intervention.

Why This Skill Exists

Growth is the most sensitive indicator of a child's overall health. Deceleration in height velocity may be the first sign of celiac disease, hypothyroidism, growth hormone deficiency, Turner syndrome, or chronic systemic illness — often preceding other symptoms by months or years. Conversely, many children evaluated for short stature have normal variants (familial short stature or constitutional delay of growth and puberty) requiring only reassurance. This skill enforces systematic differentiation between normal and pathologic growth patterns and prevents both under-investigation of worrisome trajectories and unnecessary endocrine workup for normal variants.

Checkpoint A — Intake Verification

Required Intake Questions

1. What is the child's age, sex, current height, and weight?
2. What are the serial height measurements over time (minimum 6-12 months of data)?
3. What is the birth length and birth weight? Was the child SGA?
4. What are the parents' heights (for mid-parental height calculation)?
5. What are the parents' pubertal timing histories (age of menarche for mother, growth spurt for father)?
6. Is there a family history of growth disorders, thyroid disease, or autoimmune conditions?
7. What is the child's Tanner stage (pubertal assessment)?
8. Does the child have chronic symptoms: fatigue, GI complaints, headaches, polyuria/polydipsia?
9. Is the child on any medications that might affect growth (corticosteroids, stimulants)?
10. Has a bone age X-ray been obtained?

Required Documents

• Serial height measurements plotted on WHO (< 2 years) or CDC (2-20 years) growth chart
• Birth records (length, weight, gestational age)
• Parental heights
• Bone age radiograph result (if obtained)
• Previous laboratory results (thyroid, IGF-1, celiac panel if done)
• Pubertal staging documentation

Step 1 — Growth Chart Analysis

When to Investigate

• Height < 3rd percentile (or < -2 SD) for age and sex
• Height significantly below mid-parental height target range
• Height velocity < 25th percentile for age (see velocity thresholds below)
• Crossing downward across 2 or more major percentile lines after age 2
• Height discordant with weight (weight preserved but height decelerating suggests endocrine cause)

Expected Height Velocity by Age

Height velocity < 4 cm/year in a prepubertal child aged 3+ years is abnormal and requires workup.

Mid-Parental Height (MPH) / Target Height

• Boys: (mother's height cm + father's height cm + 13) / 2
• Girls: (mother's height cm + father's height cm - 13) / 2
• Target range: MPH ± 8.5 cm (represents ~2 SD)
• If child's projected adult height (from bone age) falls outside target range, investigate

Step 2 — Bone Age Interpretation

Obtaining Bone Age

• Left hand and wrist AP radiograph (Greulich-Pyle atlas or Tanner-Whitehouse method)
• Indications: short stature evaluation, pubertal assessment, growth prediction

Interpretation Patterns

Predicted Adult Height

• Use Bayley-Pinneau tables with bone age to predict adult height
• Compare predicted adult height to mid-parental height target range
• If predicted height falls within MPH range → reassuring for normal variant
• If predicted height falls below MPH range → warrants further investigation

Step 3 — Differentiating Normal Variants from Pathology

Familial Short Stature (FSS)

• Parents short; child grows along a low percentile consistently
• Bone age = chronological age
• Puberty at normal time
• Adult height: short, but within MPH range
• Management: reassurance; no treatment indicated

Constitutional Delay of Growth and Puberty (CDGP)

• Family history of late puberty (mother's menarche > 14, father's growth spurt > 15)
• Child short for age but growing at normal velocity for bone age
• Bone age delayed 1-3 years; puberty delayed
• Adult height: usually normal (catches up during late adolescent growth spurt)
• Management: reassurance; consider short course of low-dose sex steroids at age 13-14 (boys) if psychosocial distress is significant

Red Flags for Pathologic Short Stature

• Height velocity < 4 cm/year (prepubertal)
• Height < -3 SD for age
• Disproportionate short stature (short limbs vs. trunk → skeletal dysplasia)
• Dysmorphic features
• Midline defects (cleft palate, single central incisor) → consider GH deficiency/pituitary abnormality
• Declining height percentile (crossing down) after age 2
• Weight gain with height deceleration (suggests hypothyroidism, Cushing syndrome)
• Absent or delayed puberty beyond 13 (girls) or 14 (boys)

Step 4 — Tiered Diagnostic Workup

Tier 1 — Initial Screen (For All Children With Concerning Growth)

Tier 2 — Directed by Clinical Clues

Tier 3 — Subspecialty Referral

• Pediatric endocrinology: GH stimulation testing, GH therapy initiation, precocious/delayed puberty management
• Genetics: dysmorphic features, skeletal dysplasia, suspected syndromic diagnosis
• Pediatric GI: suspected celiac disease not responding to diet, IBD, nutritional deficiency
• Pediatric nephrology: chronic kidney disease affecting growth

Step 5 — Growth Hormone Therapy Considerations

FDA-Approved Indications for GH Therapy in Children

• Growth hormone deficiency (GHD) — confirmed by stimulation testing
• Turner syndrome
• Chronic renal insufficiency (pre-transplant)
• Prader-Willi syndrome
• SGA without catch-up growth by age 2-4
• SHOX deficiency
• Idiopathic short stature (ISS): height < -2.25 SD (controversial; less insurance coverage)
• Noonan syndrome

GH Therapy Basics

• Dose: 0.024-0.034 mg/kg/day SC injection (varies by indication; higher for Turner, ISS)
• Monitoring: IGF-1 levels every 3-6 months (target age/sex-adjusted normal range; do not exceed +2 SD)
• Growth response: height velocity should increase in first year of treatment (first-year catch-up is the best predictor of long-term response)
• Side effects: injection site reactions, headache (pseudotumor cerebri — rare but check for papilledema), slipped capital femoral epiphysis, scoliosis progression, glucose intolerance

When to Stop GH Therapy

• Growth velocity < 2 cm/year
• Bone age closure (near adult height)
• Patient/family desire to discontinue
• Unacceptable side effects

Checkpoint B — Growth Disorder Management Review

• Serial height measurements plotted on appropriate growth chart (WHO or CDC)
• Height velocity calculated and compared to age norms
• Mid-parental height calculated and target range plotted
• Bone age obtained and interpreted
• Normal variants (FSS, CDGP) differentiated from pathologic growth failure
• Tier 1 labs obtained (CBC, CMP, TSH, celiac, IGF-1, IGFBP-3)
• Karyotype obtained for unexplained short stature in females
• Tier 2/3 workup directed by clinical findings
• Subspecialty referral placed if indicated (endocrine, genetics, GI)
• GH therapy criteria evaluated if GHD confirmed
• Pubertal staging documented at every growth visit
• All [VERIFY] flags resolved or escalated

Quality Audit

Guidelines

• Use WHO growth standards (birth to 2 years) and CDC growth reference charts (2-20 years) per AAP
• Follow Pediatric Endocrine Society guidelines for evaluation of short stature
• Bone age assessment: Greulich-Pyle atlas is the most widely used method; Tanner-Whitehouse for research precision
• GH stimulation testing: two failed stimulation tests required for GHD diagnosis (peak GH < 10 ng/mL on two separate tests)
• FDA-approved GH indications: GHD, Turner, CRI, PWS, SGA, SHOX deficiency, ISS, Noonan
• Turner syndrome: obtain karyotype in ALL girls with unexplained short stature (even without classic phenotypic features)
• Celiac disease: may present with isolated short stature and no GI symptoms — always screen
• Constitutional delay: bone age delay + family history of late puberty + normal growth velocity for bone age = reassurance; intervention only for significant psychosocial distress
• IGF-1 reference ranges are age- and Tanner-stage-specific; do not use adult ranges for children
• This skill produces clinical documentation; it does not replace clinical judgment